Back to Archived Journals » International Journal of Interferon, Cytokine and Mediator Research » Volume 8

Interleukin-8 in gastrointestinal inflammation and malignancy: induction and clinical consequences

Authors Cotton JA, Platnich JM, Muruve DA, Jijon H, Buret AG, Beck PL

Received 17 June 2015

Accepted for publication 24 July 2015

Published 10 May 2016 Volume 2016:8 Pages 13—34

DOI https://doi.org/10.2147/IJICMR.S63682

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Yang Wang

Peer reviewer comments 5

Editor who approved publication: Dr Randall Davis


James A Cotton,1 Jaye M Platnich,1 Daniel A Muruve,1 Humberto B Jijon,1 Andre G Buret,2 Paul L Beck,1

1Department of Medicine, 2Department of Biological Sciences, University of Calgary, Calgary, AB, Canada

Abstract: Owing to its immense surface area, the mucosal surface of the gastrointestinal (GI) tract is continually subject to numerous endogenous and exogenous antigens capable of inducing an inflammatory response in the appropriate setting. In certain individuals, these inflammatory responses may also become dysregulated and result in the development of chronic GI inflammation, such as inflammatory bowel disease. Furthermore, gastric and colonic malignant processes are extremely common and, to date, still have high mortality rates. As a result, continuing research has focused on elucidating potential molecular mechanisms involved in these processes in an attempt to understand the pathophysiology of these diseases and, potentially, aid in the development of novel therapeutics. Interleukin-8 (CXCL8) is a small molecular weight chemokine identified almost 30 years ago. Ongoing research has demonstrated that this factor contributes to a multitude of pathophysiological processes within the GI tract, including chronic GI inflammatory states, such as inflammatory bowel disease, and gastric and colonic carcinomas. This review highlights the role of CXCL8 in GI inflammation and malignancy. It describes molecular mechanisms involved in promoting and restraining CXCL8 production in GI cells and how CXCL8 contributes to the pathophysiology of a variety of GI inflammatory processes. Finally, this review describes a variety of mechanisms by which CXCL8–CXCL1/2 signaling may contribute to GI malignancy.

Keywords: CXCL8, inflammatory bowel disease, IBD, colon cancer, IL-8, Crohn’s disease, ulcerative colitis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]